Search for: "State v. Tri-State Pharmaceutical" Results 201 - 220 of 454
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Apr 2011, 1:16 pm by Bexis
Merrell–Dow Pharmaceuticals, Inc., 523 A.2d 374, 376-79 (Pa. [read post]
31 Jan 2014, 7:11 am by John Elwood
Merrell Dow Pharmaceuticals, Inc. [read post]
26 Jun 2022, 9:02 pm by Austin Sarat
They are brutal, savage events, and nothing the state tries to do can mask that reality. [read post]
10 Aug 2020, 9:38 am by David Gallacher and Keeley A. McCarty
” Here is the two-part definition: The Critical Inputs, which includes the active pharmaceutical ingredients (API), used to produce the “Essential Medicines” or “Medical Countermeasures” must be produced in the United States; and The finished drug or device must be manufactured, prepared, propagated, compounded, or processed in the United States. [read post]
30 Jul 2011, 8:22 pm by Raymond Nimmer
The state had tried to argue that regulating data was akin to regulating a commodity, but of course, it is not. [read post]
30 Jul 2011, 8:22 pm by Raymond Nimmer
The state had tried to argue that regulating data was akin to regulating a commodity, but of course, it is not. [read post]
17 Sep 2014, 9:24 am
Masahisa Yamaguchi (Chugai Pharmaceutical Co, Japan) provided a very concise and helpful summary of the biosimilars landscape. [read post]
18 Sep 2017, 1:36 am
Sometimes it is plausible that the skilled person would have tried to solve that problem, sometimes the problem construed that way may be artificial. [read post]